The systemic injection of ␥-hydroxybutyric acid (GHB) elicits spike and wave discharges (SWDs), the EEG hallmark of absence seizures, and represents a well established, widely used pharmacological model of this nonconvulsive epilepsy. Despite this experimental use of GHB, as well as its therapeutic use in narcolepsy and its increasing abuse, however, the precise cellular mechanisms underlying the different pharmacological actions of this drug are still unclear.
Introduction
Administration of ␥-hydroxybutyric acid (GHB) elicits euphoric sensations, sedation, normalization of sleep parameters, and spike and wave discharges (SWDs), the EEG hallmark of absence seizures . Some GHB effects are clinically exploited (i.e., in anesthesia, alcohol withdrawal, and narcolepsy) (Lammers et al., 1993; Kleinschmidt et al., 1998; Poldrugo and Addolorato, 1999) , whereas others underlie its illicit use as a recreational and so-called "rape" drug (Boyce et al., 2000; Nicholson and Balster, 2001 ). Experimentally, GHB-elicited SWDs are a well established model of absence seizures that are used to assess the effect of pharmacological-transgenic manipulations of neuronal channels and receptors on the expression of this paroxysmal activity Kim et al., 2001) .
The mechanisms of GHB actions, however, are unclear. The existence of (1) binding sites with a specific brain distribution [different from those of GABA A receptors (GABA A Rs) and GABA B Rs] (Bernasconi et al., 1999) , (2) high-affinity ligands (that do not displace GABA or baclofen from GABA A and GABA B sites) , and (3) biochemical and behavioral responses that are blocked by NCS 382 (the only available GHB antagonist) Schmidt et al., 1991; Hechler et al., 1993; Snead, 1996; Ferraro et al., 2001; Mehta et al., 2001 ) has led to the proposition that there are physiologically relevant brain GHB receptors (Maitre, 1997) . In contrast, other biochemical and behavioral data indicate that GHB only acts as a weak GABA B receptor agonist (Bernasconi et al., 1999) , and isolation of GHB receptor(s) has been elusive .
Electrophysiological results are also contradictory (Crunelli and Leresche, 2002b) , because in vivo studies show GHB responses that are mediated by putative GHB receptors, whereas most of the in vitro investigations highlight GABA B receptor-mediated responses, a result confirmed by data from recombinant GABA B receptors (Lingenhoehl et al., 1999) . The only exception to this scenario is the GHB-mediated modulation of Ca 2ϩ currents in NCB20 cells, which is NCS 382 sensitive (Kemmel et al., 2003) .
Sensory thalamic nuclei play a key role in SWDs (Crunelli and Leresche, 2002a) and sleep rhythms (Steriade et al., 1997) . Taking advantage of current knowledge of thalamic GABA B (Emri et al., 1996a; Ulrich and Huguenard, 1996; Kim et al., 1997; Le Feuvre et al., 1997) and putative GHB receptors (Hechler et al., 1992) , and because GHB injection in the ventrobasal (VB) thalamus elicits SWDs (Snead, 1991) , we investigated in VB thalamocortical (TC) neurons whether, and via which receptors, GHB affects corticothalamic EPSCs and GABA A ergic IPSCs originating from the nucleus reticularis thalami (NRT). We report that GHB elicits a GABA B -mediated reduction of EPSCs and IPSCs, but only 41% of the IPSCs are sensitive to concentrations Յ1 mM. Low GHB concentrations also increase slow intrathalamic oscillations evoked by cortical stimulation. These results indicate that low GHB concentrations differentially affect excitatory and inhibitory synaptic currents in TC neurons and are discussed in the context of the ability of similar brain GHB concentrations to generate SWDs in vivo.
Preliminary data have been published in abstract form (Monnier et al., 2000) .
Materials and Methods
Whole-cell recordings. A block containing the thalamus was dissected from the brain of male 10-to 22-d-old Wistar rats (mean 14 Ϯ 2), and corticothalamic (400 m thick) or horizontal (220 m thick) slices containing the NRT and ventral posterolateral and ventral posteromedial nuclei were prepared in ice-cold saline, as described by Agmon and Connors (1991) and Le Feuvre et al. (1997) , respectively, using a Vibroslice (Leica VT1000S). Slices were kept at 35°C in oxygenated saline (95% O 2 /5% CO 2 ), before being transferred, one at the time, to the experimental setup, where they were maintained at room temperature and perfused at a rate of 1-2 ml/min with an oxygenated medium of composition (in mM): 125 NaCl, 2.5 KCl, 2 CaCl 2 , 1 MgCl 2 , 1.25 NaH 2 PO 4 , 26 NaHCO 3 , and 25 glucose, pH 7.3.
Membrane currents were recorded from the soma of TC neurons visualized under Nomarski optics. Recording pipettes were pulled from borosilicate glass using a Narishige (Tokyo, Japan) micropipette puller and coated with wax. For recording synaptic currents, electrodes were filled with the following solution (in mM): 115 CsCl, 1 CaCl 2 , 5 MgCl 2 , 10 EGTA, 10 HEPES, 4 Na-ATP, 0.4 Na-GTP, 15 phosphocreatine, and 50 U/ml creatine phosphokinase, pH 7.3 (osmolarity, 305 mOsm) (electrode resistance, 1.5-2 M⍀). Once a high-resistance seal had been established, the holding potential was set to Ϫ60 mV, and the whole-cell, voltage-clamp configuration was obtained. Values of access resistance ranged from 4 to 6 M⍀ at the beginning of the recording to 4 -8 M⍀ at the end. At least 70% of these values were compensated. Patch-clamp electrodes were connected to an Axopatch 200B amplifier (Axon Instruments, Foster City, CA). Voltage protocols and acquisition were controlled by Axograph 4.8. The membrane currents were filtered by a fourpole Bessel filter set at a corner frequency of 5 kHz, digitalized on-line at a sampling rate of 10 or 20 kHz, and later analyzed using Axograph 4.8 (Axon Instruments). Data were not collected until Ն10 min after patch rupture to allow the internal and external solutions to equilibrate.
Isolation of glutamatergic EPSCs was obtained by adding the GABAergic antagonist, gabazine (1-10 M), to the perfusion medium. Isolation of GABA A IPSCs was obtained by adding to the perfusion medium the glutamate antagonists, DL-APV (50 M) and CNQX (10 M) (Eaton and Salt, 1996; Salt, 2002) . Evoked postsynaptic currents were recorded from a holding potential of Ϫ60 mV. Evoked IPSCs were elicited by extracellular electrical stimulation, using an electrode consisting of a glass pipette (6 -8 m tip diameter) filled with the extracellular medium, and a remote 100-m-thick platinum wire. The stimulating electrode was positioned 25-60 m from the recorded neuron. Evoked corticothalamic EPSCs were elicited using a bipolar metallic electrode located in the internal capsula, close to the NRT. Square pulses of 20 sec duration and 10 -40 V amplitude were applied at a frequency of 0.05 Hz to evoke EPSCs or IPSCs.
The perforated-patch technique was used to record outward K ϩ currents, because it provided more stable recordings. The patch electrodes were filled with 1 l of the following solution (in mM): 130 KCl, 10 HEPES, 1 EGTA, 1 MgCl 2 , 0.1 CaCl 2 , pH 7.3 (osmolarity, 305 mOsm). A quartz capillary was loaded with 0.5 l of pipette solution in which 100 M amphotericin B from a fresh stock solution in DMSO and 10 M fluorescein were added. The 10-m-diameter tip of the capillary was placed close to the tip of the recording pipette, and the solution was ejected once the cell-attached configuration had been obtained, leading to a rapid decrease in the series resistance. The integrity of the membrane patch was monitored with the fluorescein fluorescence.
Extracellular recordings. Extracellular recordings were performed in adult rat horizontal slices (prepared as described previously) maintained at 35°C, using an interface recording chamber and glass pipettes filled with 0.5 M NaCl (resistance, 1-5 M⍀) connected to a Neurolog 104 amplifier (Digitimer Ltd., Welwyn Garden City, UK). The extracellular medium contained (in mM): 134 NaCl, 3.75 KCl, 1.25 KH 2 PO 4 , 1 MgSO 4 , 2 CaCl 2 , 16 NaHCO 3 , 10 glucose. Multiunit activity was evoked by delivering a brief electrical stimulus (100 -200 sec; 50 -100 V) to the internal capsule using a bipolar tungsten electrode. The oscillatory index was calculated as the ratio of the first satellite peak to the central peak of the autocorrelogram, expressed as a percentage (Huntsman et al., 1999) .
Quantitative data obtained with both extracellular and patch electrode recordings are given as mean Ϯ SD, and the statistical significance was tested using Student's t test.
Drugs. Solutions containing (Ϯ)baclofen, GHB, NCS 382, NCS 356, trans-4-hydroxycrotonic acid (4-HCN), CGP 56999A, and CGP 35348 were prepared immediately before the experiment. All drugs were bath applied. We thank Novartis (Basel, Switzerland) for their gift of CGP 56999A and CGP 35348, and Dr. J. J. Bourguignon (Unité Mixte de Recherche Centre National de la Recherche Scientifique 7081, Strasbourg, France) for NCS 356. All other chemicals were purchased from Sigma and Tocris.
Results

GABA B receptors on corticothalamic afferents
Before assessing the action of GHB on corticothalamic EPSCs, we investigated the effects of the GABA B receptor agonist baclofen at this synapse, because no study has so far addressed this issue. As shown in Figures 1 and 2 , electrical stimulation of the corticothalamic afferents evoked in VB TC neurons two types of EPSCs that differ in their kinetics, with the longer-lasting type of EPSCs being recorded more frequently, as reported previously by Kao and Coulter (1997) .
Application of (Ϯ)baclofen dose-dependently and reversibly decreased the amplitude of corticothalamic EPSCs in all neurons tested ( Fig. 1 A, B) . The effect of baclofen reached steady-state between 2 and 3 min from the beginning of the application, and the recovery was obtained between 10 and 12 min after the start of the washout. The reduction observed with 0.1, 0.5, 1, 10, and 20 M baclofen was 15 Ϯ 4% (n ϭ 7), 47 Ϯ 9 (n ϭ 8), 55 Ϯ 6% (n ϭ 9), 78 Ϯ 11% (n ϭ 14), and 85 Ϯ 6% (n ϭ 4), respectively (IC 50 , 0.48 M) (Fig. 1C) . The decreases obtained with 10 and 20 M baclofen were not statistically different ( p ϭ 0.05), suggesting that 10 M baclofen already provides a maximal activation of the GABA B receptors present at this synapse. The GABA B receptor antagonists CGP 35348 (1 mM) (n ϭ 3) or CGP 56999A (100 nM) (n ϭ 15) not only fully antagonized the 10 M baclofen-induced reduction of the EPSC, but also increased the amplitude of the EPSC above the control level ( Fig. 1 A, B) , as has already been shown for both the sensory EPSP (Emri et al., 1996a ) and the NRT-derived IPSPs in TC neurons (Le Feuvre et al., 1997) . No difference in baclofen potency and the effect of GABA B antagonists was observed between EPSCs with different kinetics.
Effect of GHB on the corticothalamic EPSC
Having established the action of baclofen, we then investigated the effect of GHB on electrically evoked corticothalamic EPSCs. Application of GHB reversibly decreased the amplitude of these EPSCs in 96% of TC neurons. The effect of GHB reached steadystate between 2 and 3 min from the beginning of the application, and the recovery was obtained between 10 and 12 min after the start of the washout. No effect was observed with 100 M GHB (n ϭ 3), whereas 250 M evoked a reduction (17 Ϯ 3%) in seven of eight neurons (Fig. 2 A) . Increasing the GHB concentration to 500 M, 1 mM, 10 mM, and 20 mM elicited a decrease of 27 Ϯ 10% (n ϭ 34 of 36), 25 Ϯ 10% (n ϭ 6 of 6), 56 Ϯ 11% (n ϭ 5 of 5), and 61 Ϯ 13% (n ϭ 5 of 5), respectively (Figs. 2 B, 4A, B) . In the two neurons in which 500 M GHB was ineffective, subsequent application of baclofen markedly decreased the amplitude of the EPSC (Fig. 2C) .
The GHB-elicited reduction of the corticothalamic EPSC was antagonized by CGP 56999A (100 nM) in 3 of 3, 10 of 12, and 4 of 4 neurons tested with 250 M, 500 M, and 1 mM GHB, respectively (Fig. 2 A) . Similar to what had been observed with baclofen, CGP 56999A produced an increase over the control amplitude in the presence of GHB (Fig. 2 A) , and no differences in the effect of GHB were observed between EPSCs with different kinetics.
These results indicate that the totality of GHB effects on the corticothalamic EPSCs recorded in TC neurons occurs through activation of GABA B receptors. In the hippocampus, however, an effect of GHB on the EPSPs and IPSPs evoked in CA1 neurons after stimulation of Schaeffer collateral-commissural fibers could still be observed when GHB was applied in the continuous presence of the GABA B receptor antagonists CGP 35348 (500 M) (Berton et al., 1999) or CGP 55845 (1 M) (Cammalleri et al., 2002) . To match this experimental paradigm, we applied GHB in the continuous presence of 1 mM CGP 35348, a concentration that fully antagonizes the response to a maximal concentration of baclofen (Fig. 2 D) . Also in this condition, however, GHB was never capable of inducing a reduction of the corticothalamic EPSC (n ϭ 8) (Fig. 2 D) . Effect of GHB on the corticothalamic EPSC. A1, GHB (250 M) decreases the amplitude of the EPSC by 11%. This effect is antagonized by CGP56999A (100 nM), which also increases the EPSC size by 16% compared with control. A2, Superimposition of the individual synaptic currents used to build up the averages presented in A1 (control in black; GHB in gray). B1, GHB (500 M) produces a reversible 22% decrease of the EPSC. B2, Superimposition of the individual synaptic currents used to build up the averages presented in B1 (control in black; GHB in gray). C, Recordings from one of the few TC neurons in which GHB fails to decrease the EPSC amplitude show that 10 M baclofen decreases this synaptic current by 90%. Perfusion with the excitatory amino acid antagonists (CNQX and APV) blocks the electrically evoked corticothalamic EPSC. D, In the continuous presence of the GABA B antagonist CGP35348 (1 mM), GHB (500 M) has no effect on the EPSC. The lack of effect of 10 M baclofen on the EPSC after washout of GHB demonstrates that this concentration of CGP 35348 fully blocks presynaptic GABA B receptors. Each trace in A1, B1, C, and D is the average of 10 -20 EPSCs.
Effect of GHB on NRT-mediated IPSCs GHB also decreased the amplitude of NRT-derived GABA A IPSCs with a similar potency as against the EPSCs (see below), but at low concentrations (250 M-1 mM) it was effective on only 41% of the IPSCs. In particular, 250 M GHB did not produce any effect on 13 of 14 neurons (Fig. 3A) , whereas a 14% reduction was observed in 1 neuron (Fig. 4 A, B) . Increasing the GHB concentration to 500 M induced a 25 Ϯ 8% reduction of the IPSCs in 21 of 42 neurons (Fig. 3B) , whereas 1 mM GHB produced a 29 Ϯ 10% reduction in 9 of 19 neurons (Fig. 4 A, B) ; however, application of 10 mM GHB induced a 54 Ϯ 10% decrease in every TC neuron tested (n ϭ 7) (Figs. 3C, 4A, B) .
The GHB-induced reduction of the NRT-derived IPSCs was always fully antagonized by CGP 56999A (100 nM) (n ϭ 1 and 4, for 250 and 500 M GHB, respectively) (Fig. 3B) . In addition, in the continuous presence of CGP 56999A (100 nM), application of GHB (500 M) never decreased the IPSC amplitude (n ϭ 10) (Fig. 3D) .
In 10 of the 31 neurons that were insensitive to either 500 M or 1 mM GHB, we were able to apply baclofen (5-10 M) after washout of GHB. In each of these 10 neurons, baclofen decreased the IPSC amplitude by the same amount as in those neurons in which GHB was active (Fig. 3E) .
It has been claimed that some of the actions of GHB observed in vitro when using high micromolar to low millimolar concentrations could be caused by its conversion to GABA via the GHB dehydrogenase (Hechler et al., 1997) . If this were the case under the experimental conditions used to record IPSCs, one would have expected to see a change in holding current caused by the continuous activation of GABA A receptors. No change in holding current, however, was observed in any experiments on the IPSCs, nor has any change been reported during similar experiments in cortex and hippocampus (Jensen and Mody, 2001 ).
Effects of NCS 382
To completely exclude the involvement of putative GHB receptors in the action of GHB on thalamic synaptic currents, we then looked at the effect of the putative GHB receptor antagonist NCS 382. We started by investigating the action of this compound applied alone, because no study has thoroughly addressed this issue so far.
NCS 382 at a concentration of 50 -100 M, which has been shown to be effective against GHB action in NCB20 cells (Kemmel et al., 1998) , had no effect on the EPSC amplitude (n ϭ 5) (Fig. 5A) . At concentrations Ն300 M, however, NCS 382 produced a reversible increase in the EPSC amplitude. In particular, at 300 M, 500 M, and 1 mM, NCS 382 increased the EPSC by 10 and 20% (n ϭ 2), 10 and 12% (n ϭ 2), and 24 Ϯ 4% (n ϭ 6), respectively (Fig. 5B) . Conversely, application of 1 mM NCS 382 decreased the amplitude of ISPCs by 21 Ϯ 5% (n ϭ 4) (Fig. 5C) .
Despite the narrow range within which NCS 382 alone had no action on synaptic currents, we then tested the ability of NCS 382 to antagonize the effect of GHB. Application of NCS 382 at 100 M-1 mM had no effect on the GHB-elicited reduction of the EPSC (Fig. 6 A) , or it prevented the full block of the GHB response by a GABA B receptor antagonist. In addition, at concentration Ն500 M, NCS 382 could elicit an additional decrease to that produced by GHB (Fig. 6 B) (i.e., 20% reduction in one of three neurons tested with 500 M GHB and 18% in two of seven neurons tested with 1 mM GHB), as reported previously for the sensory EPSP in the same thalamic nucleus (Emri et al., 1996b) .
Similarly, application of 500 M or 1 mM NCS 382 did not antagonize the effect of GHB (250 M, n ϭ 1; 500 M, n ϭ 4) on the IPSC amplitude (Fig. 6C) ; however, in three of five neurons tested with 1 mM NCS 382, it produced an additional 18 Ϯ 7% decrease in the IPSC amplitude. Overall, therefore, NCS 382 shows a number of nonspecific actions on synaptic currents that drastically limit its use. Effect of GHB on the NRT-derived IPSC. A1, GHB (250 M) has no effect on the amplitude of the GABA A IPSC. A2, Superimposition of the individual synaptic currents used to build up the averages presented in A1 (control in black; GHB in gray). The IPSCs recorded in control condition and during GHB application have been offset for clarity. B1, GHB (500 M) decreases the amplitude of the IPSC by 20%. This effect is antagonized by CGP 56999A (100 nM). B2, Superimposition of the individual synaptic currents used to build up the averages presented in B1 (control in black; GHB in gray). C, GHB at 10 mM reversibly decreases the IPSC amplitude by 48%. D1, In the continuous presence of CGP 56999A (100 nM), GHB (500 M) has no effect on the IPSC. D2, Superimposition of the traces shown in D1. E, Recordings from one of the VB TC neurons in which 500 M GHB fails to decrease the IPSC amplitude show that 10 M baclofen reduces this synaptic current by 72%. Each trace in A1, B1, and C-E is the average of 10 -20 IPSCs.
Lack of effect of NCS 356 and trans-4-hydroxycrotonic acid
Although GHB actions on synaptic currents were fully blocked by GABA B receptor antagonists, it might be that GHB receptor may be disclosed using more potent agonists. We therefore tested the effect of NCS 356 and 4-HCN, two high-affinity ligands of putative GHB receptors that have been suggested to possess agonistlike actions (Hechler et al., , 1993 . Application of NCS 356 (500 M) failed to produce any change in the amplitude of the corticothalamic EPSC (n ϭ 18) (Fig. 7A) or the NRT-derived GABA A IPSC (n ϭ 8) (Fig. 7B ). In the same neurons, however, subsequent application of either 500 M GHB or 1-10 M baclofen produced the usual reduction in the synaptic current amplitude (Fig. 7 A, B) . 4-HCN (500 M) was also unable to affect the IPSC (n ϭ 3) (Fig. 7C) .
Postsynaptic action of GHB
GHB has already been shown to hyperpolarize TC neurons, an effect that is mediated by activation of postsynaptic GABA B receptors and insensitive to NCS 382 (Williams et al., 1995) . Because in the continuous presence of GABA B antagonists the unmasking of a GHB receptor-mediated response on hippocampal synaptic currents has been reported recently (Berton et al., 1999; Cammalleri et al., 2002) , we wonder whether under similar conditions a postsynaptic effect of GHB on TC neurons could also be highlighted.
From a holding potential of Ϫ60 mV, GHB (500 M-10 mM; n ϭ 32) produced an outward current (Fig. 8 A, B) , with an ED 50 of 1.2 mM. In the continuous presence of CGP 56999A, however, at a concentration (300 nM) that fully blocked the maximal response to baclofen (10 M) (n ϭ 4) (Fig. 8C) , GHB was unable to elicit any outward current (n ϭ 12) (Fig. 8 B) .
Action of GHB on intrathalamic oscillations
Having established the action of GHB on corticothalamic EPSCs, NRT-evoked IPSCs, and TC neurons, we examined the ability of this drug to affect intrathalamic oscillations using extracellular recordings of multiunit activity in the VB. Stimulation of the cortical afferents, achieved by delivering a brief stimulus to the internal capsule, elicited slow intrathalamic oscillations of firing activity (frequency, 1.5 Ϯ 0.4 Hz; n ϭ 9 recordings in nine different slices) consisting of action potential bursts in few TC neurons (1.8 Ϯ 0.4 U) with an oscillatory index of 51 Ϯ 7% (Fig. 9A) . After application of 250 M GHB, the oscillatory response to internal capsule stimulation comprised a larger number of neurons (4.7 Ϯ 0.5 U; p Ͻ 0.001) and occurred at a higher frequency (3.1 Ϯ 1.0 Hz; p Ͻ 0.01), with an increased oscillatory index (72 Ϯ 8%; p Ͻ 0.001) (Fig. 9B-D) . Interestingly, in some experiments (n ϭ 3), the oscillatory activity recorded in the presence of GHB became self-sustained, i.e., it no longer required electrical stimulation of the cortical afferents (data not shown). All of these effects of GHB were reversed after removal of the drug from the perfusion medium (frequency, 1.3 Ϯ 0.4 Hz; number of units, 2.2 Ϯ 0.3; oscillatory index, 62 Ϯ 6%) (Fig. 9A-D) . Application of 500 M GHB, on the other hand, abolished evoked intrathalamic oscillations in four of five cases (Fig. 9E) .
Discussion
The main conclusion of this investigation is that in the concentration range (250 -500 M) that elicits SWDs, GHB instates an imbalance between the excitatory and inhibitory drives to TC neurons because it decreases 96% of corticothalamic glutamatergic EPSCs but only 43% of the NRT GABA A ergic IPSCs. Low GHB concentrations (250 M) also increase intrathalamic oscillations evoked by cortical stimulation.
In addition, our results demonstrate that these thalamic GHB effects are mediated by GABA B receptors and strongly question the use of NCS 382 and NCS 356 and 4-HCN as putative GHB receptor antagonist and agonists, respectively.
GABA B versus GHB receptors
That all GHB actions in VB are mediated by GABA B receptors is in agreement with previous in vitro electrophysiological experiments in another thalamic nucleus (Williams et al., 1995; Emri et al., 1996b) and any brain areas examined so far, i.e., substantia nigra (Harris et al., 1989) , hippocampus (Xie and Smart, 1992b; King et al., 1997) , ventral tegmental area (VTA) (Madden and Johnson, 1998) , and cortex (Jensen and Mody, 2001) . Berton et al. (1999) and Cammalleri et al. (2002) , however, reported that in the presence of CGP 35348 (500 M) or CGP 55845 (1 M), application of GHB (600 M) decreases EPSPs or GABA A IPSPs, respectively, in CA1 neurons in vitro, an effect abolished by NCS 382. Using a similar protocol, we did not detect any GHB receptor-mediated action on thalamic EPSCs and IPSCs. Although this discrepancy may reflect a real difference between thalamus and hippocampus, it is likely that GHB was still acting on presynaptic GABA B receptors in these two hippocampal studies, because 1 mM is necessary to fully block presynaptic GABA B receptors in this area (Davies et al., 1991) . Indeed, Berton et al. (1999) and Cammalleri et al. (2002) did not test whether presynaptic GABA B receptors were fully blocked. Furthermore, although these studies reported no effect of 500 M NCS 382 alone, an increase (11 and 65% at 100 M and 2 mM, respectively) has been observed in hippocampal field potentials (King et al., 1997) , Figure 7 . Lack of effect of NCS356 and 4-HCN on EPSCs and IPSCs. A, NCS356 (500 M) has no effect on the EPSC, whereas the decrease induced by baclofen (1 M) indicates that the synaptic current in this neuron is sensitive to GABA B receptor activation. B, NCS356 (500 M) fails to affect the NRT-derived IPSC, whereas the decrease induced by baclofen (10 M) indicates that the synaptic current in this neuron is sensitive to GABA B receptor activation. C1, 4-HCN (500 M) has no effect on the GABA A IPSC amplitude. C2, Superimposition of the traces shown in C1. Each trace in A-C is the average of 10 -20 EPSCs or IPSCs. Figure 8 . GHB-elicited outward current. A, Application of GHB dose-dependently activates an outward current in a VB TC neuron (A1). A2 shows the dose-response curve of the effect of GHB in one neuron. Numbers in the plot refer to the order of application, as indicated in A1. For comparison, the inset shows the outward current activated in the same neuron by 10 M baclofen. B, The outward current elicited by 1 mM GHB is fully antagonized by CGP 56999A (300 nM). C, The outward current elicited by 10 M baclofen is fully antagonized by CGP 56999A (300 nM).
ity was detected only on postsynaptic elements in the VB (i.e., on TC neurons) (Kulik et al., 2002) . The lack of GABA B immunoreactivity in VB presynaptic elements is surprising when compared with this and previous electrophysiological studies and has been explained by the existence of yet unidentified GABA B clones (Kulik et al., 2002) . In this respect, our findings that ϳ60% of GABA A IPSCs in VB are unaffected by low GHB concentrations but show a normal sensitivity to baclofen would suggest the existence of thalamic GABA B autoreceptor subtype(s) with a low sensitivity to GHB. Interestingly, the threshold concentration for GABA Bmediated effects of GHB in cortex and hippocampus (Jensen and Mody, 2001 ) is 10-fold higher than in thalamus.
Mechanism of GHB-elicited SWDs and decreased states of vigilance
A preferential effect of GHB on basal glutamate versus GABA release in vivo was shown in VB (Banerjee and Snead, 1995) but not in cortex (Hu et al., 2000) , although the significance of changes in basal thalamic release for the EEG expression of a paroxysmal activity is unclear. Electrophysiologically, low (250 M-1 mM) GHB concentrations hyperpolarize TC neurons (Williams et al., 1995) and decrease with a similar potency sensory EPSPs (Emri et al., 1996b) , corticothalamic EPSCs, and 40% of GABA A IPSCs in VB, whereas the remaining IPSCs are unaffected (this study). On the basis of these results, and because SWDs can be elicited by direct injection of GHB into the VB (Snead, 1991) , we suggest that a substantial component of the mechanism underlying the generation of SWDs by systemic GHB is caused by an imbalance of the physiological excitatory and inhibitory drives to TC neurons in favor of an increased inhibition. This would not only tend to slightly hyperpolarize TC neurons and decrease their afferent corticothalamic and sensory excitatory volleys, but would also leave the TC neuron population with a substantial proportion of unaltered NRT phasic inhibition, thus helping to impose that periodic inhibition that sculptures the electrical behavior of TC neuron during this paroxysmal activity (Steriade and Contreras, 1995; Pinault et al., 1998; Huntsman et al., 1999; Blumenfeld and McCormick, 2000; Tancredi et al., 2000; D'Arcangelo et al., 2002; Slaght et al., 2002) . The ability of low (250 M) GHB concentrations to increase absence-like intrathalamic oscillations clearly supports this view. It should be pointed out, however, that in addition to directly activating corticothalamic excitatory synapses, internal capsule stimulation will also strongly excite NRT neurons by activating both corticothalamic and thalamocortical fibers. Furthermore, because the NRT plays a key role in the maintenance and initiation of intrathalamic oscillations, the involvement of specific GHB-mediated effects in this nucleus should not be discounted when attempting to understand the pro-rhythmic actions of this drug. Whether an imbalance of excitatory and inhibitory drives might account for other GHB actions also remains to be elucidated, although it is worth noting that in VTA a differential control of EPSCs and IPSCs was recently suggested to underlie the rewarding properties of nicotine (Mansvelder et al., 2002) .
Another critical feature of the GHB model of absence seizures that can also be explained by our results is the finding that SWDs are evoked within a narrow range of GHB concentrations (240 -500 M in the rat), because higher concentrations lead to a progressive slowing of the EEG associated with increasingly strong sedation and sleep promotion (Snead et al., 1976; Snead, 1991) . Our results show that at a GHB concentration of 250 M, the imbalance between the excitatory and inhibitory drives to TC neurons is already present and that slow intrathalamic oscillations are increased. At 500 M, although the preferential effect on EPSCs versus IPSCs remains, the oscillations are partly abolished, probably because the (postsynaptic) activation of G-protein gated inward rectifying K ϩ current (GIRK) is stronger. At even higher concentrations, the dampening of both excitatory and inhibitory inputs, together with the increasing GIRK activation, would result in a stronger hyperpolarization of TC neurons, necessary to express those intrinsic-network activities associated with states of progressively decreasing vigilance (Steriade, 2000; Hughes et al., 2002) . This thalamic action, together with similar effects on cortical neurons (Godbout et al., 1995; Jensen and Mody, 2001) , might well account for the sedation and normalization of sleep patterns, which are exploited in the illicit use of GHB and its clinical use in narcolepsy, respectively.
